0.8626
5.03%
-0.0474
Handel nachbörslich:
.86
-0.0026
-0.30%
Schlusskurs vom Vortag:
$0.91
Offen:
$0.94
24-Stunden-Volumen:
1.78M
Relative Volume:
2.25
Marktkapitalisierung:
$71.22M
Einnahmen:
$101.21M
Nettoeinkommen (Verlust:
$-569.00K
KGV:
-1.0269
EPS:
-0.84
Netto-Cashflow:
$-56.88M
1W Leistung:
-16.90%
1M Leistung:
-26.76%
6M Leistung:
-54.28%
1J Leistung:
-34.53%
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Firmenname
Cytomx Therapeutics Inc
Sektor
Branche
Telefon
650.515.3185
Adresse
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Vergleichen Sie CTMX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
CTMX | 0.8626 | 71.22M | 101.21M | -569.00K | -56.88M | -0.84 |
VRTX | 467.12 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 762.38 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 567.35 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 232.27 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 101.83 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-05-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
2024-05-09 | Hochstufung | Wedbush | Neutral → Outperform |
2024-05-06 | Hochstufung | Jefferies | Hold → Buy |
2024-04-22 | Hochstufung | JP Morgan | Underweight → Neutral |
2022-11-14 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
2022-07-07 | Herabstufung | Jefferies | Buy → Hold |
2022-07-07 | Herabstufung | Mizuho | Buy → Neutral |
2022-07-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
2022-07-07 | Herabstufung | Wedbush | Outperform → Neutral |
2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
2022-01-18 | Hochstufung | Barclays | Underweight → Overweight |
2021-11-15 | Eingeleitet | BTIG Research | Buy |
2021-05-28 | Herabstufung | Barclays | Equal Weight → Underweight |
2021-03-29 | Eingeleitet | JP Morgan | Overweight |
2021-03-23 | Hochstufung | Jefferies | Hold → Buy |
2020-09-22 | Herabstufung | Guggenheim | Buy → Neutral |
2020-06-01 | Herabstufung | Jefferies | Buy → Hold |
2020-05-14 | Bestätigt | H.C. Wainwright | Buy |
2020-03-24 | Hochstufung | Wedbush | Neutral → Outperform |
2020-03-04 | Eingeleitet | Barclays | Equal Weight |
2019-11-20 | Eingeleitet | Guggenheim | Buy |
2019-11-11 | Herabstufung | Wedbush | Outperform → Neutral |
2019-06-13 | Eingeleitet | Mizuho | Buy |
2019-05-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
2019-03-11 | Eingeleitet | Barclays | Overweight |
2018-11-26 | Eingeleitet | Piper Jaffray | Overweight |
2018-10-15 | Eingeleitet | Goldman | Neutral |
2018-09-13 | Eingeleitet | H.C. Wainwright | Buy |
2018-06-01 | Eingeleitet | SunTrust | Buy |
2018-01-05 | Eingeleitet | Citigroup | Buy |
2017-09-08 | Eingeleitet | Wedbush | Outperform |
2017-03-27 | Eingeleitet | H.C. Wainwright | Buy |
2017-03-02 | Eingeleitet | Instinet | Buy |
2017-01-03 | Herabstufung | Oppenheimer | Outperform → Perform |
2015-11-02 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Cytomx Therapeutics Inc Aktie (CTMX) Neueste Nachrichten
CytomX stock touches 52-week low at $0.98 amid market challenges - Investing.com Canada
TANG CAPITAL MANAGEMENT LLC Acquires Shares in CytomX Therapeuti - GuruFocus.com
Analysis of JANUS HENDERSON GROUP PLC's Recent Transaction in Cy - GuruFocus.com
HC Wainwright Has Bullish Estimate for CTMX FY2024 Earnings - Defense World
HC Wainwright Has Positive Outlook for CTMX FY2024 Earnings - MarketBeat
CytomX Therapeutics' SWOT analysis: biotech stock's potential in cancer treatment - Investing.com UK
CytomX Therapeutics (NASDAQ:CTMX) Earns "Neutral" Rating from HC Wainwright - MarketBeat
CytomX Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
CytomX Therapeutics (NASDAQ:CTMX) Stock Price Crosses Below 50 Day Moving AverageTime to Sell? - MarketBeat
CytomX Therapeutics Inc earnings beat by $0.24, revenue topped estimates - Investing.com Australia
CytomX Therapeutics (CTMX) Q3 Earnings and Revenues Top Estimates - MSN
CytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: - GuruFocus.com
CytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... - Yahoo Finance
CytomX Therapeutics: Q3 Earnings Snapshot - Darien Times
CytomX Therapeutics Reports Q3 Progress and Growth - TipRanks
CytomX stock touches 52-week low at $0.98 amid market shifts - Investing.com India
CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q3 202 - GuruFocus.com
Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q3 2024 Result - Yahoo Finance
Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Price Target at $5.77 - Defense World
CytomX Therapeutics (CTMX) Set to Announce Earnings on Thursday - MarketBeat
CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024 - The Manila Times
Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) PT at $5.77 - MarketBeat
Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues - Simply Wall St
CytomX stock plunges to 52-week low at $1.03 amid market challenges - Investing.com India
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Down 10.5% in September - MarketBeat
CytomX Therapeutics Inc (CTMX) rating upgrades by Piper Sandler - Knox Daily
Trading Day Triumph: CytomX Therapeutics Inc (CTMX) Ends at 1.09, a -5.22 Surge/Plunge - The Dwinnex
CTMX Stock: A Comprehensive Analysis and Forecast - The InvestChronicle
CytomX Therapeutics (NASDAQ:CTMX) & Immuneering (NASDAQ:IMRX) Head to Head Comparison - Defense World
Squarepoint Ops LLC Has $243,000 Stock Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
Selling Buzz: CytomX Therapeutics Inc [CTMX] Chief Business Officer Landau Jeffrey B sells 4,181 shares of the company – Knox Daily - Knox Daily
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
There is no way CytomX Therapeutics Inc (CTMX) can keep these numbers up - SETE News
Forefront Analytics LLC Has $78,000 Stock Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
Wall Street SWOT: CytomX Therapeutics stock shows promise amid clinical trials - Investing.com
CytomX Therapeutics Inc [NASDAQ: CTMX] Sees Increase in Stock Value - Knox Daily
Investors in cash trouble should check out CytomX Therapeutics Inc (CTMX) - SETE News
Is it possible to buy CytomX Therapeutics Inc(CTMX) shares at a good price now? - US Post News
Metastatic Cancer Drugs Market Outlook, Insights, and Size: 2024-2033 - WhaTech
CTMX stock rated an Overweight by Piper Sandler - Knox Daily
Investor’s Toolkit: Key Ratios for Assessing CytomX Therapeutics Inc (CTMX)’s Performance - The Dwinnex
Altamira Therapeutics Reports Narrowed Losses - TipRanks
CytoDyn Announces Preliminary Findings in Study with SMC Laboratories - StockTitan
Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results - StockTitan
This trade activity should not be overlooked: Cytokinetics Inc (CYTK) - SETE News
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down - MSN
XTX Topco Ltd Makes New $889,000 Investment in Churchill Downs Incorporated (NASDAQ:CHDN) - MarketBeat
Renaissance Technologies LLC Takes Position in ChampionX Co. (NASDAQ:CHX) - MarketBeat
Tucows Inc. (NASDAQ:TCX) CEO Elliot Noss Sells 5,700 Shares of Stock - Defense World
Finanzdaten der Cytomx Therapeutics Inc-Aktie (CTMX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cytomx Therapeutics Inc-Aktie (CTMX) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Landau Jeffrey B | Chief Business Officer |
Aug 20 '24 |
Sale |
1.23 |
4,181 |
5,139 |
119,056 |
BELVIN MARCIA | SVP, Chief Scientific Officer |
Aug 20 '24 |
Option Exercise |
0.00 |
11,250 |
0 |
179,829 |
BELVIN MARCIA | SVP, Chief Scientific Officer |
Aug 20 '24 |
Sale |
1.23 |
4,181 |
5,139 |
175,648 |
ROWLAND LLOYD A | General Counsel |
Aug 20 '24 |
Option Exercise |
0.00 |
11,250 |
0 |
134,978 |
ROWLAND LLOYD A | General Counsel |
Aug 20 '24 |
Sale |
1.23 |
4,181 |
5,139 |
130,797 |
Ogden Christopher | Chief Financial Officer |
Aug 20 '24 |
Option Exercise |
0.00 |
6,875 |
0 |
110,061 |
Ogden Christopher | Chief Financial Officer |
Aug 20 '24 |
Sale |
1.23 |
1,984 |
2,439 |
108,077 |
McCarthy Sean A. | CEO |
Aug 20 '24 |
Option Exercise |
0.00 |
37,500 |
0 |
671,749 |
McCarthy Sean A. | CEO |
Aug 20 '24 |
Sale |
1.23 |
13,898 |
17,082 |
657,851 |
McCarthy Sean A. | CEO |
Mar 26 '24 |
Option Exercise |
1.57 |
109,768 |
172,874 |
634,249 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):